Waldencast PLC

Waldencast PLC(WALD)の株式分析

$0.879

-0.041 (-4.69%)終値時点

Loading chart…
高値
0.990
始値
0.930
出来高加重平均価格
0.91
出来高
277.02K
時価総額
478.98M
安値
0.861
売買代金
252.12K
EV/EBITDA(TTM)
-0.59

Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States.

www.waldencast.com

AI分析 of Waldencast PLC (WALD)

売り

Waldencast PLC is not a good buy right now due to significant financial losses and declining stock performance. The current price is $0.88, which is down 48.57% year-to-date. The RSI is at 26.413, indicating that the stock is oversold, but the forward P/E ratio is extremely high at 45.045, suggesting that the stock may be overvalued relative to its earnings potential. The main risk is the net margin, which was -140.03% in Q2 2025, indicating severe profitability issues.

バリュエーション指標

Waldencast PLC(WALD)の現在の予想PERは45.05で、5年平均は20.89です。

予想PER

適正
5年平均 P/E
20.89
現在のP/E
45.05
割高
140.86
割安
-99.09

予想EV/EBITDA

大幅な割安
5年平均 EV/EBITDA
13.82
現在のEV/EBITDA
-0.59
割高
20.28
割安
7.36

予想PSR

割安
5年平均 P/S
1.79
現在のP/S
0.35
割高
2.88
割安
0.69

Alphio AI による WALD の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%WALD

$3.01

シナリオ価格

基

基本

基本 · 50%WALD

$2.59

シナリオ価格

弱

弱気

弱気 · 25%WALD

$2.24

シナリオ価格

イベントタイムライン

2026-10-15 (ET)

17:00:00

Waldencast Files Form 15 to Terminate Registration

2026-09-24 (ET)

17:00:00

Waldencast Files Form 25 with SEC to Deregister Shares

2026-09-14 (ET)

07:00:00

Waldencast Announces Voluntary Delisting from Nasdaq

2026-09-01 (ET)

19:00:00

Middle East Violence Escalation Weighs on Markets, Tech Stocks Under Pressure

2026-06-15 (ET)

09:30:00

Waldencast Receives FDA Approval for Obagi saypha ChIQ Injectable Hyaluronic Acid Gel

ニュース

WALD のよくある質問 — Alphio AI が回答

Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States. It operates in the Consumer Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Waldencast PLC is not a good buy right now due to significant financial losses and declining stock performance. The current price is $0.88, which is down 48.57% year-to-date. The RSI is at 26.413, indicating that the stock is oversold, but the forward P/E ratio is extremely high at 45.045, suggesting that the stock may be overvalued relative to its earnings potential. The main risk is the net margin, which was -140.03% in Q2 2025, indicating severe profitability issues.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める